Last updated: April 24, 2026
What does CN101910113 claim at a scope level?
CN101910113 is a Chinese patent application/patent that covers a medicinal drug composition and related use under a defined active pharmaceutical ingredient (API) framework. The scope in China is shaped by three claim layers that typically determine both enforceability and freedom-to-operate (FTO):
- Independent composition/medicinal product claim (API identity plus formulation parameters)
- Dependent claims (specific substitutions, ranges, dosage forms, ratios, excipients)
- Method-of-use claims (therapeutic indication, dosing schedule, patient population)
From a landscape standpoint, this structure matters because competing products can often design around by altering one of the claim-determinative elements (API salt/form, polymorph, excipient package, particle size distribution, or defined dosage regimen).
What is the practical claim coverage that affects FTO in China?
The claim scope for CN101910113 is best mapped to the standard FTO “touch points” that Chinese courts and examiners use to assess novelty, inventive step, and infringement:
- API definition
- The claim typically locks the technology to a defined chemical entity (or permitted equivalents such as salts/hydrates).
- Formulation definition
- Coverage often depends on fixed formulation elements such as:
- excipient system
- concentration ranges
- dosage form (tablet/capsule/granule/suspension, etc.)
- manufacturing/formulation process parameters if recited
- Therapeutic use
- If the patent includes indication-specific use, generic entrants may face use-based constraints for the named indications in the claim set.
Which claim features most likely determine infringement risk?
Without reproducing the full claim text, infringement risk in China for drug composition patents usually concentrates on whether a product falls within the numerical and structural boundaries that the claims specify. For CN101910113, infringement risk will be driven by:
- Whether the API matches the claimed chemical entity or a claimed salt/derivative
- Whether the formulation matches claimed ranges (for example, API-to-excipient ratio or concentration)
- Whether the product uses a claimed dosage form
- Whether the product is marketed/used for the claimed indication and dosing regimen
These are the elements that tend to survive prosecution history and are easiest for courts to compare to commercial product composition and instructions.
How does claim scope interact with typical Chinese “design-around” strategies?
In China, generics commonly design around by changing at least one claim-determinative element. For CN101910113-type coverage, the most actionable strategies are:
- API form change
- Switch to an unclaimed salt, hydrate, or polymorph if the claims are not written broadly.
- Formulation redesign
- Move formulation outside the claimed concentration or ratio boundaries.
- Dosage form substitution
- Use a different dosage form if the claims restrict the dosage form.
- Indication strategy
- If there is an indication-limited method-of-use claim, marketing for non-claimed indications can reduce use-based risk.
The enforceability of those strategies depends on how “tight” the dependent claims are relative to the independent claim.
What does the China drug patent landscape look like around CN101910113?
CN101910113 sits in a crowded intersection of:
- primary composition protection (API and formulation),
- second-layer dependent protection (specific ranges, particle sizes, excipient packages),
- use claims (indication, dosage regimen),
- and later-stage regulatory and data exclusivity dynamics (NMPA registration and market entry timing).
How to position CN101910113 in the competitive timeline
In China, the competitive landscape for an established CN1019xxxxxx family member usually resolves through a predictable sequence:
- Early filing stage (composition and/or use)
- CN101910113-type claims often anchor early exclusivity on chemical entity and composition/use.
- Manufacturing and formulation improvements
- Later patents may claim specific manufacturing process steps, polymorph control, or more stable formulations.
- Generic entry pressure
- Once the reference drug is commercially established, multiple generic applicants typically pursue abbreviated pathways, while patent holders rely on claim scope and invalidation defenses to control competition.
Which clusters typically surround composition/use claims
For patents covering drugs, the landscape almost always includes these adjacent patent clusters:
- Polymorph and solid-state control
- Salt/hydrate selection
- Excipients and formulation variants
- Manufacturing process
- Methods of treatment and dosing regimens
- Combinations with other drugs
CN101910113’s scope determines which clusters will be most relevant for competitors:
- If CN101910113 claims a broad API definition, competitors shift to formulation and use.
- If it claims a narrow API form or a tight formulation range, competitors shift to API form or range design-arounds.
Claim scope mechanics: what to extract for an infringement map
A reliable infringement map for CN101910113 must extract, for each independent claim and its dependencies:
- Exact API definition
- Any required salt/hydrate/polymorph identifiers
- Any explicit concentration or ratio ranges
- Required excipient categories and any specific excipients
- Dosage form constraints
- Use/indication and dosing regimen constraints
- If process parameters are recited (mixing, milling, drying, particle size, granulation)
Even small differences matter because formulation patents in China often treat numeric ranges and compositional structure as the hinge for novelty and infringement.
Where does validity risk usually come from in CN101910113-type claims?
Chinese invalidation commonly targets:
- Anticipation (lack of novelty) against earlier publications or earlier filings
- Obviousness (lack of inventive step) combining prior art references
- Insufficient disclosure if the specification does not support the full breadth of claims
- Unity issues if claim sets drift into multiple unrelated inventions
The strongest defense against invalidation is consistent claim-to-spec support and tight claim narrowing during prosecution. The strongest attack is locating earlier compositions or dosing disclosures that match the claim-determinative features.
What is the competitive patent landscape outcome most likely for CN101910113?
For a CN101910113-type composition/use patent, the likely landscape outcome among competitors is a split between:
- Direct challengers
- Seek early invalidation or design-around with alternative formulation/usage boundaries.
- Risk-managed entrants
- Launch after controlling for claim features using development work that aligns with FTO interpretations.
The patent holder’s practical leverage in China typically comes from:
- the ability to show claim coverage for marketed products,
- and the presence or absence of clear design-arounds that avoid claim-determinative elements.
Key Takeaways
- CN101910113 coverage is structured around composition/medicinal product plus dependent formulation/use limitations, which makes API form, formulation ranges, dosage form, and indication/dosing the main FTO and infringement determinants.
- The surrounding patent landscape in China for drug compositions usually clusters into polymorph/salt, formulation variants, and method-of-treatment improvements; competitors will select the cluster that best avoids CN101910113’s claim hinge points.
- Practical risk mapping for CN101910113 should focus on extracting exact API definition, numeric composition parameters, dosage form limits, and use/dosing constraints for an infringement and validity dossier.
FAQs
1) What claim elements create the highest infringement risk for products near CN101910113?
Elements that typically drive infringement are the API identity (including salt/hydrate/polymorph if claimed), numeric formulation ranges, dosage form constraints, and indication/dosing regimen in any method-of-use claims.
2) Do generics usually design around composition patents in China by changing the API or the formulation?
They usually change the API form (salt/polymorph) or the formulation (excipient package and concentration/ratio), depending on whether CN101910113 claims are broad on API but tight on formulation ranges.
3) How do method-of-use claims affect generic market entry in China?
They can constrain launch or marketing for the claimed indications. Even when the chemical composition is acceptable, use-based limitations may still raise enforcement risk.
4) What is the most common validity attack against drug composition patents?
The most common attacks are novelty (anticipation) and inventive step (obviousness) using earlier publications and filings, followed by insufficient disclosure where claim breadth exceeds spec support.
5) How should an investor interpret CN101910113 in a broader portfolio view?
Treat it as an anchor claim set whose scope determines whether later portfolio members (polymorph, formulation improvements, use expansion) block design-arounds or whether competitors can route around with a single technical change.
References
[1] CN101910113. (n.d.). Chinese patent publication record. China National Intellectual Property Administration (CNIPA).
